ACIU — AC Immune SA Share News
0.000.00%
Last trade - 00:00- $260.54m
- $173.47m
- CH₣3.57m
Factbox: Roche's drug failure extends long list of Alzheimer's trial setbacks
Brief: AC Immune SA Reports Q3 Loss Per Share Of CHF 0.16
Factbox: Eisai-Biogen Alzheimer's drug success follows many failures
Factbox: Eisai-Biogen Alzheimer's drug success follows many failures
Brief: Ac Immune Partner LMI Progresses Tau PET Tracer PI-2620 Into Late-Stage Development In Alzheimer’S Disease
Brief: AC Immune Receives Grant From Michael J Fox Foundation
Brief: AC Immune To Present Data From Phase II Crenezumab Alzheimer’s Prevention Initiative Study
Brief: Ac Immune Reports Q2 2022 Financial Results
Swiss stocks - Factors to watch on June 24
U.S. STOCKS ON THE MOVE-PROG Holdings Inc, Perion Network Ltd, Olaplex Holdings Inc
U.S. STOCKS ON THE MOVE-Ebix Inc, KLA Corp, Snowflake Inc
AC Immune hits record low as Alzheimer's treatment fails in mid-stage study
U.S. STOCKS ON THE MOVE-Commercial Metals Co, Intel Corp, Mastercard Inc
Roche's study flop marks yet another Alzheimer's setback (updated)
U.S. STOCKS ON THE MOVE-Twitter Inc, Netflix Inc, Tesla Inc
AC Immune slumps as Alzheimer's treatment fails in mid-stage study
Brief: AC Immune Provides Update On Study Evaluating Crenezumab In Autosomal Dominant Alzheimer's Disease
AC Immune SA reports results for the quarter ended in March - Earnings Summary
Brief: AC Immune Reports Q1 2022 Financial Results